Can denosumab be a substitute, competitor, or complement to bisphosphonates?.
- Author:
Su Young KIM
1
;
Hwoe Gyeong OK
;
Christof BIRKENMAIER
;
Kyung Hoon KIM
Author Information
- Publication Type:Review
- Keywords: Bisphosphonates; Bone mineral density; Bone resorption; Denosumab; Hypocalcemia; Monoclonal antibodies; Osteoclast; Osteoporosis; Osteoprotegerin; RANK ligand
- MeSH: Antibodies, Monoclonal; Biomarkers; Bone Density; Bone Resorption; Compliance; Denosumab*; Diphosphonates*; Half-Life; Hematopoietic Stem Cells; Hypersensitivity; Hypocalcemia; Jaw; Miners; Musculoskeletal Pain; NF-kappa B; Osteoblasts; Osteoclasts; Osteonecrosis; Osteoporosis; Osteoprotegerin; RANK Ligand
- From:The Korean Journal of Pain 2017;30(2):86-92
- CountryRepublic of Korea
- Language:English
- Abstract: Osteoblasts, originating from mesenchymal cells, make the receptor activator of the nuclear factor kappa B ligand (RANKL) and osteoprotegerin (OPG) in order to control differentiation of activated osteoclasts, originating from hematopoietic stem cells. When the RANKL binds to the RANK of the pre-osteoclasts or mature osteoclasts, bone resorption increases. On the contrary, when OPG binds to the RANK, bone resorption decreases. Denosumab (AMG 162), like OPG (a decoy receptor), binds to the RANKL, and reduces binding between the RANK and the RANKL resulting in inhibition of osteoclastogenesis and reduction of bone resorption. Bisphosphonates (BPs), which bind to the bone mineral and occupy the site of resorption performed by activated osteoclasts, are still the drugs of choice to prevent and treat osteoporosis. The merits of denosumab are reversibility targeting the RANKL, lack of adverse gastrointestinal events, improved adherence due to convenient biannual subcutaneous administration, and potential use with impaired renal function. The known adverse reactions are musculoskeletal pain, increased infections with adverse dermatologic reactions, osteonecrosis of the jaw, hypersensitivity reaction, and hypocalcemia. Treatment with 60 mg of denosumab reduces the bone resorption marker, serum type 1 C-telopeptide, by 3 days, with maximum reduction occurring by 1 month. The mean time to maximum denosumab concentration is 10 days with a mean half-life of 25.4 days. In conclusion, the convenient biannual subcutaneous administration of 60 mg of denosumab can be considered as a first-line treatment for osteoporosis in cases of low compliance with BPs due to gastrointestinal trouble and impaired renal function.
